Compare NOMD & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMD | NUVB |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | 298 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2015 | N/A |
| Metric | NOMD | NUVB |
|---|---|---|
| Price | $10.34 | $4.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $12.50 | $11.38 |
| AVG Volume (30 Days) | 1.5M | ★ 4.3M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | $1.45 | $58.18 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.99 | $1.57 |
| 52 Week High | $18.33 | $9.75 |
| Indicator | NOMD | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 37.13 |
| Support Level | $9.47 | $4.07 |
| Resistance Level | $10.46 | $5.23 |
| Average True Range (ATR) | 0.40 | 0.29 |
| MACD | 0.10 | -0.06 |
| Stochastic Oscillator | 86.89 | 14.09 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.